Current Report Filing (8-k)
2022年4月2日 - 2:50AM
Edgar (US Regulatory)
0000350737
false
OCEAN BIO CHEM INC
0000350737
2022-03-31
2022-03-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 31, 2022
OCEAN BIO-CHEM, INC.
(Exact name of registrant as specified in charter)
Florida |
|
0-11102 |
|
59-1564329 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
4041 S.W. 47 Avenue, Fort Lauderdale, Florida |
|
33314 |
(Address of principal executive offices) |
|
(Zip Code) |
(954) 587-6280
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
Common Stock, $0.01 par value |
OBCI |
The NASDAQ Stock Market |
Item 2.02. Results of Operations and Financial Condition
On March 31, 2022, Ocean Bio-Chem, Inc. (the “Company”)
issued a press release announcing financial results for the fourth quarter and twelve months ended December 31, 2021. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report.
The information furnished pursuant to Item 2.02 of this Current Report,
including the exhibit furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into future
filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless
the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by
reference therein.
Item 9.01 Financial Statements and Exhibits
The Company is furnishing the following exhibit to this Current Report:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
OCEAN BIO-CHEM, INC. |
|
|
|
Date: April 1, 2022 |
By: |
/s/ Jeffrey
S. Barocas |
|
|
Jeffrey S. Barocas |
|
|
Chief Financial Officer |
Ocean Bio Chem (NASDAQ:OBCI)
過去 株価チャート
から 4 2024 まで 5 2024
Ocean Bio Chem (NASDAQ:OBCI)
過去 株価チャート
から 5 2023 まで 5 2024
Real-Time news about Ocean Bio Chem Inc (ナスダック市場): 0 recent articles
その他のOcean Bio Chem Incニュース記事